Irinotecan
Information
- Drug Name
- Irinotecan
- Description
- Entry(CIViC)
- 21
CIViC
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05312398 | Active, not recruiting | Phase 2 | CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen | July 15, 2021 | June 15, 2026 |
| NCT03678883 | Active, not recruiting | Phase 2 | 9-ING-41 in Patients With Advanced Cancers | January 4, 2019 | November 2025 |
| NCT04095221 | Active, not recruiting | Phase 1/Phase 2 | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | September 17, 2019 | September 2024 |
| NCT05217069 | Active, not recruiting | Phase 2 | FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC | September 27, 2019 | August 1, 2024 |
| NCT03641313 | Active, not recruiting | Phase 2 | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer | November 16, 2020 | July 1, 2024 |
| NCT03533582 | Active, not recruiting | Phase 2/Phase 3 | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | May 24, 2018 | June 30, 2026 |
| NCT04697628 | Active, not recruiting | Phase 3 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | February 22, 2021 | August 5, 2025 |
| NCT03493048 | Active, not recruiting | Phase 2 | Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM | April 15, 2018 | June 2025 |
| NCT05330429 | Active, not recruiting | Phase 2 | Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | July 8, 2022 | November 2026 |
| NCT04094688 | Active, not recruiting | Phase 3 | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer | September 30, 2019 | July 2025 |
| NCT04879368 | Active, not recruiting | Phase 3 | RegoNivo vs Standard of Care Chemotherapy in AGOC | June 1, 2021 | June 1, 2026 |
| NCT03323034 | Active, not recruiting | Phase 1 | Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma | January 11, 2018 | September 22, 2024 |
| NCT03279237 | Active, not recruiting | Phase 1 | A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers | October 24, 2017 | September 2023 |
| NCT04067115 | Active, not recruiting | Phase 1/Phase 2 | SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients | January 5, 2021 | June 30, 2024 |
| NCT03206151 | Active, not recruiting | Phase 3 | CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer | December 12, 2017 | June 30, 2024 |
| NCT04238819 | Active, not recruiting | Phase 1/Phase 2 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | November 9, 2020 | October 2028 |
| NCT05253846 | Active, not recruiting | Phase 2 | Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 | January 25, 2022 | October 30, 2028 |
| NCT04525014 | Active, not recruiting | Phase 1 | RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors | January 26, 2023 | December 31, 2024 |
| NCT03189706 | Active, not recruiting | Early Phase 1 | Study of Chemoimmunotherapy for High-Risk Neuroblastoma | June 12, 2017 | June 2024 |
| NCT03017326 | Active, not recruiting | Phase 3 | Paediatric Hepatic International Tumour Trial | August 24, 2017 | August 1, 2027 |
| NCT02967289 | Active, not recruiting | Phase 3 | IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting | March 27, 2017 | June 2027 |
| NCT04513951 | Active, not recruiting | Phase 2 | AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients | April 1, 2020 | July 31, 2024 |
| NCT04492033 | Active, not recruiting | Phase 1/Phase 2 | A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients | June 22, 2020 | July 31, 2025 |
| NCT04034459 | Active, not recruiting | Phase 2 | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | November 25, 2016 | December 31, 2023 |
| NCT02934529 | Active, not recruiting | Phase 3 | Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | March 2015 | December 2024 |
| NCT05342636 | Active, not recruiting | Phase 1/Phase 2 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | July 27, 2022 | September 21, 2026 |
| NCT04117945 | Active, not recruiting | Phase 2 | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | March 3, 2020 | March 31, 2025 |
| NCT05435313 | Active, not recruiting | Phase 2 | Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | July 12, 2022 | February 2024 |
| NCT05678257 | Active, not recruiting | Phase 2 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | April 18, 2023 | March 2025 |
| NCT04481204 | Active, not recruiting | Phase 2 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study | April 18, 2023 | April 6, 2025 |
| NCT04109924 | Active, not recruiting | Phase 2 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | December 27, 2019 | July 17, 2024 |
| NCT03970252 | Active, not recruiting | Early Phase 1 | Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer | July 24, 2019 | April 2026 |
| NCT02919787 | Active, not recruiting | Phase 2/Phase 3 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | September 2016 | April 30, 2026 |
| NCT02308527 | Active, not recruiting | Phase 2 | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children | July 2013 | February 2026 |
| NCT03773367 | Active, not recruiting | Phase 2 | Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. | December 14, 2018 | May 31, 2026 |
| NCT02192359 | Active, not recruiting | Phase 1 | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | March 7, 2016 | December 30, 2024 |
| NCT04447092 | Active, not recruiting | Phase 2 | Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | July 1, 2020 | December 31, 2025 |
| NCT03709680 | Active, not recruiting | Phase 1/Phase 2 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | May 24, 2019 | February 25, 2025 |
| NCT02138617 | Active, not recruiting | Phase 2 | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | May 2014 | June 1, 2027 |
| NCT03699319 | Active, not recruiting | Phase 1/Phase 2 | CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer | December 7, 2018 | September 23, 2024 |
| NCT04385277 | Active, not recruiting | Phase 2 | Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) | December 31, 2020 | September 26, 2024 |
| NCT04251715 | Active, not recruiting | Phase 2 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma | April 28, 2021 | November 30, 2024 |
| NCT01871766 | Active, not recruiting | Phase 2 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | December 4, 2013 | June 2030 |
| NCT01864109 | Active, not recruiting | Phase 2 | Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | May 2013 | May 2027 |
| NCT01858168 | Active, not recruiting | Phase 1 | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma | July 2013 | December 2024 |
| NCT04743661 | Active, not recruiting | Phase 2 | 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma | April 4, 2022 | October 30, 2030 |
| NCT00336856 | Completed | Phase 2 | Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy | June 2006 | June 2011 |
| NCT00345163 | Completed | Phase 2 | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN) | July 2006 | September 2007 |
| NCT00352521 | Completed | Phase 2 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma | April 2006 | July 2009 |
| NCT00353015 | Completed | Phase 2 | Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract | March 2003 | July 2009 |
| NCT00354978 | Completed | Phase 2 | Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients | January 2005 | March 2011 |
| NCT00387660 | Completed | Phase 2 | Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer | October 2001 | January 2009 |
| NCT00394433 | Completed | Phase 2 | Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | September 2006 | October 2016 |
| NCT00400114 | Completed | Phase 2 | Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer | September 25, 2006 | September 19, 2016 |
| NCT00404495 | Completed | Phase 2 | Combination of Irinotecan and Temozolomide in Children With Brain Tumors. | April 2007 | December 2011 |
| NCT00418938 | Completed | Phase 2 | SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | November 1, 2006 | April 1, 2013 |
| NCT00436072 | Completed | Phase 1 | ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer | February 2007 | August 2012 |
| NCT00437268 | Completed | Phase 2 | A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer | March 2007 | May 2009 |
| NCT00447967 | Completed | Phase 2 | Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients | July 2004 | September 2008 |
| NCT00452634 | Completed | Phase 2 | Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC) | April 2006 | May 2010 |
| NCT00457691 | Completed | Phase 3 | Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer | June 2007 | March 2010 |
| NCT00463073 | Completed | Phase 2 | Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas | August 2006 | December 2008 |
| NCT00463203 | Completed | Phase 2 | Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy | March 2007 | June 2011 |
| NCT00469443 | Completed | Phase 3 | Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC | December 2006 | February 2010 |
| NCT00483834 | Completed | Phase 2 | A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer | December 2006 | July 2011 |
| NCT00497497 | Completed | Phase 1 | A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g) | October 2007 | September 2010 |
| NCT00507091 | Completed | Phase 1 | Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination | August 2005 | June 2008 |
| NCT00509860 | Completed | Phase 2 | Irinotecan (Camptosar) in Patients With Advanced Sarcomas | March 2003 | January 2012 |
| NCT00522665 | Completed | Phase 1/Phase 2 | Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer | August 2007 | February 2015 |
| NCT00539877 | Completed | Phase 1 | Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding | October 2004 | August 2007 |
| NCT00540943 | Completed | Phase 1 | Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer | July 13, 2007 | May 3, 2010 |
| NCT00551213 | Completed | Phase 2 | A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) | November 21, 2007 | June 4, 2009 |
| NCT00563316 | Completed | Phase 1 | Effect of Panitumumab on the Pharmacokinetics of Irinotecan | March 2008 | June 2010 |
| NCT00590031 | Completed | Phase 2 | Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan. | November 2002 | December 2009 |
| NCT00594984 | Completed | Phase 1/Phase 2 | Phase I/II Combination With Irinotecan- Erbitux | May 2008 | December 2012 |
| NCT00597402 | Completed | Phase 2 | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | July 2007 | May 2013 |
| NCT00614965 | Completed | Phase 2 | Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV | November 2006 | March 2010 |
| NCT00639327 | Completed | Phase 2/Phase 3 | Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer | March 2008 | June 2011 |
| NCT00642577 | Completed | Phase 3 | A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer. | July 2007 | December 2010 |
| NCT00671372 | Completed | Phase 1 | A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer | July 2006 | March 2012 |
| NCT00682786 | Completed | Phase 2 | Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma | October 2002 | August 2010 |
| NCT00689624 | Completed | Phase 2 | Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer | July 2007 | December 2010 |
| NCT00695292 | Completed | Phase 2 | Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer | June 2008 | September 2012 |
| NCT00708773 | Completed | Phase 1 | Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors | February 2006 | August 2016 |
| NCT00718757 | Completed | Phase 1 | Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | January 2005 | January 2009 |
| NCT00730158 | Completed | Phase 2 | A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer | December 2008 | June 2018 |
| NCT00762255 | Completed | Phase 1 | A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma | September 2008 | July 2013 |
| NCT00778102 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer. | October 2008 | October 2013 |
| NCT00786669 | Completed | Phase 1 | A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors | October 2008 | November 2012 |
| NCT00792363 | Completed | Phase 2 | Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations | November 2008 | August 2011 |
| NCT00813072 | Completed | Phase 2 | Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | November 2007 | December 2010 |
| NCT00819728 | Completed | Phase 2 | Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer | June 2000 | January 2003 |
| NCT00827684 | Completed | Phase 2 | Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations | March 2009 | June 2011 |
| NCT00836277 | Completed | Phase 2 | Phase II Study of Irinotecan and Panitumumab | May 2009 | August 2015 |
| NCT00851045 | Completed | Phase 2 | Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer | October 2009 | October 2011 |
| NCT00856375 | Completed | Phase 2 | NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer | December 2008 | December 2014 |
| NCT00857246 | Completed | Phase 2 | Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer | July 2005 | October 2015 |
| NCT00876993 | Completed | Phase 1 | Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors | September 2008 | September 2015 |
| NCT00890786 | Completed | Early Phase 1 | A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas | May 2009 | December 2017 |
| NCT00891930 | Completed | Phase 2 | Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab | May 2009 | July 2013 |
| NCT00911820 | Completed | Phase 2 | Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | July 2009 | August 2013 |
| NCT00925015 | Completed | Phase 1 | Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016) | June 17, 2009 | December 6, 2010 |
| NCT00940303 | Completed | Phase 2 | OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer | June 2009 | February 2014 |
| NCT00941655 | Completed | Phase 3 | Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial | July 22, 2009 | June 18, 2012 |
| NCT00967330 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma | June 2010 | September 2014 |
| NCT00979017 | Completed | Phase 2 | Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | November 2009 | January 2013 |
| NCT00980239 | Completed | Phase 1 | HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver | September 2009 | August 2015 |
| NCT00990912 | Completed | Phase 1/Phase 2 | A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002) | January 2004 | November 2005 |
| NCT00993044 | Completed | Phase 1 | A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin | September 2009 | February 2013 |
| NCT01008475 | Completed | Phase 1/Phase 2 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer | October 2009 | April 2015 |
| NCT01046864 | Completed | Phase 1 | Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) | February 2010 | June 2014 |
| NCT00003594 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer | October 1998 | October 2004 |
| NCT00005626 | Completed | Phase 2 | Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) | February 1998 | November 2003 |
| NCT00022698 | Completed | Phase 2 | Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer | May 2001 | December 2004 |
| NCT00034502 | Completed | Phase 1/Phase 2 | A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. | ||
| NCT00037804 | Completed | Phase 1 | Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction | ||
| NCT00048126 | Completed | Phase 2 | A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | July 2001 | January 2005 |
| NCT00048139 | Completed | Phase 2 | A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | October 2001 | June 2005 |
| NCT00057473 | Completed | Phase 2 | A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors | February 2003 | February 2004 |
| NCT00057837 | Completed | Phase 2 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | July 14, 2004 | August 2012 |
| NCT00061932 | Completed | Phase 2 | Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach | April 2003 | November 2013 |
| NCT00062842 | Completed | Phase 1 | Study of Irinotecan on a Weekly Schedule in Children | September 9, 1998 | September 12, 2006 |
| NCT00063141 | Completed | Phase 3 | Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer | April 2003 | October 2007 |
| NCT00068692 | Completed | Phase 3 | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer | October 15, 2003 | November 15, 2016 |
| NCT00072852 | Completed | Phase 2 | Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine | November 2003 | May 2007 |
| NCT00081289 | Completed | Phase 2 | Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer | March 2004 | December 2016 |
| NCT00111761 | Completed | Phase 2 | Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer | July 2002 | October 2008 |
| NCT00126256 | Completed | Phase 3 | Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer | February 2002 | February 2006 |
| NCT00136955 | Completed | Phase 2 | Irinotecan Study For Cervical Cancer | June 2004 | May 2008 |
| NCT00137852 | Completed | Phase 2 | Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer | January 2002 | September 2017 |
| NCT00138060 | Completed | Phase 4 | Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants | June 2005 | December 2008 |
| NCT00139711 | Completed | Phase 2 | Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer | March 2003 | June 2006 |
| NCT00144378 | Completed | Phase 3 | Irinotecan Versus Only Best Supportive Care for Gastric Cancer | October 2002 | |
| NCT00165464 | Completed | Phase 2 | Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer | August 2001 | April 2009 |
| NCT00165490 | Completed | Phase 2 | Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer | August 2004 | November 2014 |
| NCT00176774 | Completed | Phase 2 | Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma | February 2001 | April 2004 |
| NCT00183846 | Completed | Phase 1 | Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers | December 2000 | July 2009 |
| NCT00183859 | Completed | Phase 1 | Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan | September 1999 | April 2009 |
| NCT00191984 | Completed | Phase 2 | A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer | June 2004 | May 2008 |
| NCT00193349 | Completed | Phase 2 | Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer | September 2002 | December 2007 |
| NCT00193375 | Completed | Phase 2 | Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer | August 2003 | May 2008 |
| NCT00193596 | Completed | Phase 3 | Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site | September 2003 | June 2009 |
| NCT00209625 | Completed | Phase 1/Phase 2 | Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer | April 2000 | November 2004 |
| NCT00209638 | Completed | Phase 1/Phase 2 | Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer | May 2000 | April 2003 |
| NCT00213486 | Completed | Phase 2 | Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial | June 2002 | December 2004 |
| NCT00215501 | Completed | Phase 1 | Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies | November 2001 | September 2008 |
| NCT00215982 | Completed | Phase 2 | Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer | December 2004 | July 2007 |
| NCT00215995 | Completed | Phase 2 | Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas | July 2003 | May 2007 |
| NCT00222443 | Completed | Phase 1 | Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy | September 2004 | December 2007 |
| NCT00230399 | Completed | Phase 2 | Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer | June 2003 | March 2008 |
| NCT00248482 | Completed | Phase 2 | Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer | February 2002 | January 2008 |
| NCT00251797 | Completed | Phase 1 | A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors | March 2000 | June 2006 |
| NCT00254137 | Completed | Phase 2 | Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. | September 2004 | November 2006 |
| NCT00294931 | Completed | Phase 2 | Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | February 2006 | January 2009 |
| NCT00298675 | Completed | Phase 1 | Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors | March 2006 | May 2011 |
| NCT00308529 | Completed | Phase 2 | Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer | March 2006 | January 2009 |
| NCT00332163 | Completed | Phase 2 | Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy | April 2006 | September 2008 |
| NCT01075048 | Completed | Phase 1/Phase 2 | ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | January 26, 2010 | February 20, 2015 |
| NCT01084330 | Completed | Phase 2 | Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer | April 2010 | May 2012 |
| NCT01091259 | Completed | Phase 2 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | March 2010 | May 2015 |
| NCT01116271 | Completed | Phase 2 | Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec | April 2010 | July 2012 |
| NCT01131078 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum | June 2005 | November 2012 |
| NCT01139138 | Completed | Phase 1/Phase 2 | Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer | June 2010 | June 2017 |
| NCT01163396 | Completed | Phase 2 | First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer | July 2007 | April 2010 |
| NCT01183780 | Completed | Phase 3 | A Study in Second Line Metastatic Colorectal Cancer | December 2, 2010 | June 20, 2016 |
| NCT01220063 | Completed | Phase 2 | RSHF in Colorectal Cancer | October 19, 2007 | August 2018 |
| NCT01225744 | Completed | Phase 2 | Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy | April 2009 | May 2013 |
| NCT01226719 | Completed | Phase 2 | FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only | December 2010 | March 2014 |
| NCT01274624 | Completed | Phase 1 | Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer | December 2010 | November 2018 |
| NCT01286818 | Completed | Phase 1 | A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) | February 2011 | March 2012 |
| NCT01296763 | Completed | Phase 1 | Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer | January 2011 | February 2016 |
| NCT01304602 | Completed | Phase 1 | A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer | February 2011 | October 2015 |
| NCT01374425 | Completed | Phase 2 | Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) | August 2011 | July 2015 |
| NCT01394939 | Completed | Phase 1/Phase 2 | Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | January 2012 | October 2015 |
| NCT01413022 | Completed | Phase 1 | FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | April 2012 | September 2016 |
| NCT01442649 | Completed | Phase 2 | Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab | December 2010 | December 31, 2017 |
| NCT01442935 | Completed | Phase 2 | Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | February 2011 | January 2021 |
| NCT01451632 | Completed | Phase 1 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | October 2011 | June 2014 |
| NCT01467986 | Completed | Phase 2 | Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | August 2013 | September 30, 2020 |
| NCT01518413 | Completed | Phase 1 | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | December 2011 | January 2015 |
| NCT01528046 | Completed | Phase 1 | Metformin in Children With Relapsed or Refractory Solid Tumors | September 24, 2012 | February 3, 2020 |
| NCT01558869 | Completed | Phase 2 | Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma | April 2012 | December 2016 |
| NCT01560949 | Completed | Phase 2 | Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas | June 14, 2012 | February 20, 2019 |
| NCT01588990 | Completed | Phase 4 | A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer | June 26, 2012 | September 30, 2016 |
| NCT01593228 | Completed | Phase 3 | Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | May 2012 | September 2016 |
| NCT01601535 | Completed | Phase 1/Phase 2 | Study of MLN8237 in Combination With Irinotecan and Temozolomide | May 2012 | July 25, 2018 |
| NCT01634555 | Completed | Phase 2 | A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI | October 2012 | February 2018 |
| NCT01650428 | Completed | Phase 2 | Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery | April 2013 | February 14, 2019 |
| NCT01652482 | Completed | Phase 2 | Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) | October 2012 | November 2014 |
| NCT01653470 | Completed | Phase 1 | Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors | October 12, 2012 | May 8, 2017 |
| NCT01660711 | Completed | Phase 2 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | July 2012 | August 22, 2018 |
| NCT01670721 | Completed | Phase 3 | Colorectal Cancer Metastatic | August 2012 | June 2015 |
| NCT01675128 | Completed | Phase 1/Phase 2 | ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer | August 2012 | December 2015 |
| NCT01677884 | Completed | Phase 2 | Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy | November 2012 | February 2016 |
| NCT01803282 | Completed | Phase 1 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | March 29, 2013 | April 23, 2019 |
| NCT01821612 | Completed | Early Phase 1 | Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer | May 2013 | June 15, 2018 |
| NCT01822613 | Completed | Phase 1 | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | July 26, 2013 | June 3, 2016 |
| NCT01858649 | Completed | Phase 2 | Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI. | May 2013 | May 2019 |
| NCT01859858 | Completed | Phase 1 | Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors | June 2013 | October 5, 2016 |
| NCT01862003 | Completed | Phase 2 | Phase I/II Trial of Antagonism of HER in GI Cancer | May 2014 | August 2, 2019 |
| NCT01867697 | Completed | Phase 2 | Nordic 8 - A Phase II Trial | May 2012 | March 2019 |
| NCT01882868 | Completed | Phase 2 | A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan | July 2013 | August 2015 |
| NCT01896856 | Completed | Phase 1/Phase 2 | Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer | October 23, 2013 | August 26, 2019 |
| NCT01926197 | Completed | Phase 3 | Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer | August 14, 2013 | September 30, 2022 |
| NCT01928290 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer | November 8, 2013 | October 28, 2019 |
| NCT01930552 | Completed | Phase 1 | A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies | September 2013 | December 2014 |
| NCT01941316 | Completed | Phase 1/Phase 2 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | November 2013 | July 1, 2019 |
| NCT01959139 | Completed | Phase 1/Phase 2 | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer | January 23, 2014 | November 9, 2023 |
| NCT01963182 | Completed | Phase 2 | Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer | October 2013 | December 9, 2019 |
| NCT01999270 | Completed | Phase 1 | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | April 2013 | May 2016 |
| NCT02024607 | Completed | Phase 1/Phase 2 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | January 2014 | November 2019 |
| NCT02035137 | Completed | Phase 2 | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat | July 2014 | February 26, 2021 |
| NCT02044120 | Completed | Phase 1 | ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma | May 2014 | January 2021 |
| NCT02096354 | Completed | Phase 2 | A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer | May 2014 | April 13, 2018 |
| NCT02119026 | Completed | Phase 2 | Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer | February 2011 | August 31, 2017 |
| NCT02129257 | Completed | Phase 2 | Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer | May 26, 2014 | September 25, 2017 |
| NCT02143219 | Completed | Phase 2 | Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer | July 31, 2014 | November 25, 2020 |
| NCT02157792 | Completed | Phase 1 | M6620 First in Human Study | December 10, 2012 | March 11, 2020 |
| NCT02172976 | Completed | Phase 2/Phase 3 | Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma | November 2014 | May 2020 |
| NCT02231723 | Completed | Phase 1 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer | August 2014 | June 2020 |
| NCT02244632 | Completed | Phase 1/Phase 2 | Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer | September 2014 | January 30, 2020 |
| NCT02256800 | Completed | N/A | Escalated Dose of Irinotecan in mCRC | August 13, 2014 | November 30, 2017 |
| NCT02292758 | Completed | Phase 2 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | December 12, 2014 | September 27, 2019 |
| NCT02324543 | Completed | Phase 1/Phase 2 | Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer | February 2015 | February 2020 |
| NCT02327169 | Completed | Phase 1 | A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies | January 14, 2015 | July 2, 2018 |
| NCT02387138 | Completed | Phase 1 | A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan | April 2014 | September 2018 |
| NCT02392793 | Completed | Phase 1 | Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies | March 25, 2015 | August 30, 2019 |
| NCT02414009 | Completed | Phase 2 | Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients | September 2014 | July 30, 2019 |
| NCT02489903 | Completed | Phase 2 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | June 2015 | December 6, 2021 |
| NCT02511132 | Completed | Phase 2 | A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma | February 10, 2016 | December 23, 2020 |
| NCT02539537 | Completed | Phase 3 | A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma | October 23, 2015 | September 25, 2023 |
| NCT02558868 | Completed | Phase 2 | Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer | September 1, 2015 | December 31, 2017 |
| NCT02558959 | Completed | Phase 2 | Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer | September 1, 2015 | December 31, 2017 |
| NCT02564263 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) | December 1, 2015 | March 14, 2022 |
| NCT02582970 | Completed | Phase 4 | A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum | May 2005 | April 2008 |
| NCT02588105 | Completed | Phase 1 | Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer | November 10, 2015 | July 26, 2022 |
| NCT02596503 | Completed | Phase 1 | A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors | October 21, 2015 | January 24, 2020 |
| NCT02596828 | Completed | Phase 2 | Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | April 2016 | April 2021 |
| NCT02620423 | Completed | Phase 1 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | December 2015 | August 2018 |
| NCT02625623 | Completed | Phase 3 | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | December 28, 2015 | November 13, 2019 |
| NCT02640365 | Completed | Phase 1 | A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer | November 18, 2015 | December 7, 2016 |
| NCT02641873 | Completed | Phase 1 | A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer | December 2015 | January 2017 |
| NCT02645864 | Completed | Phase 1 | Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma | January 2016 | December 2018 |
| NCT02677116 | Completed | Phase 1 | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | August 29, 2016 | April 3, 2019 |
| NCT02720068 | Completed | Phase 1 | Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) | May 2, 2016 | March 15, 2024 |
| NCT02753127 | Completed | Phase 3 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | June 2016 | May 12, 2021 |
| NCT02906059 | Completed | Phase 1 | Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | September 2016 | March 12, 2020 |
| NCT02928224 | Completed | Phase 3 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | October 13, 2016 | November 10, 2022 |
| NCT03098030 | Completed | Phase 2/Phase 3 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | June 1, 2017 | March 26, 2020 |
| NCT03099382 | Completed | Phase 3 | Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer | May 5, 2017 | May 6, 2019 |
| NCT03136055 | Completed | Phase 2 | Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas | June 20, 2017 | October 31, 2021 |
| NCT03139331 | Completed | Phase 1 | PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma | June 6, 2017 | September 30, 2020 |
| NCT03141034 | Completed | Phase 2 | Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma | November 1, 2017 | April 14, 2023 |
| NCT03142516 | Completed | Phase 2 | FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status | October 31, 2017 | January 21, 2021 |
| NCT03146377 | Completed | Phase 2 | Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer | April 2014 | December 2016 |
| NCT03184870 | Completed | Phase 1/Phase 2 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors | August 8, 2017 | June 14, 2023 |
| NCT03231722 | Completed | Phase 3 | First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS | September 13, 2017 | June 24, 2022 |
| NCT03279289 | Completed | Phase 2 | Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen | October 25, 2017 | February 9, 2023 |
| NCT03295084 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors | July 15, 2015 | October 30, 2018 |
| NCT03318445 | Completed | Phase 1 | Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | January 12, 2018 | March 1, 2021 |
| NCT03374254 | Completed | Phase 1 | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) | February 16, 2018 | July 18, 2023 |
| NCT03430843 | Completed | Phase 3 | A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | January 26, 2018 | December 28, 2022 |
| NCT03454620 | Completed | Phase 1/Phase 2 | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | April 2, 2018 | January 10, 2022 |
| NCT03493061 | Completed | Phase 2 | A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM | February 1, 2018 | December 30, 2022 |
| NCT03535727 | Completed | Phase 1/Phase 2 | A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer | June 21, 2018 | October 3, 2022 |
| NCT03721653 | Completed | Phase 2 | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | November 30, 2018 | August 31, 2023 |
| NCT03778593 | Completed | Phase 2 | FOLFIRINOX for 2nd-line Treatment of BTC | March 1, 2019 | January 14, 2021 |
| NCT03933449 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study | December 29, 2016 | March 14, 2022 |
| NCT04072445 | Completed | Phase 2 | Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer | October 18, 2019 | August 13, 2021 |
| NCT04074343 | Completed | Phase 1 | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | August 26, 2019 | July 21, 2022 |
| NCT04247984 | Completed | Phase 2 | A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer | May 1, 2018 | January 31, 2022 |
| NCT04299880 | Completed | Phase 1 | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | February 24, 2020 | May 30, 2021 |
| NCT04770623 | Completed | Phase 2 | Docetaxel and Irinotecan in Gastric Cancer | March 5, 2021 | January 9, 2023 |
| NCT04790448 | Completed | Phase 1/Phase 2 | Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer | July 27, 2020 | December 31, 2021 |
| NCT04808791 | Completed | Phase 2 | iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | October 27, 2021 | July 21, 2023 |
| NCT05178745 | Completed | A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection | September 7, 2016 | May 27, 2022 | |
| NCT05278728 | Completed | Phase 1/Phase 2 | Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer | July 2009 | December 2013 |
| NCT05595889 | Not yet recruiting | Phase 2 | Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | December 1, 2022 | September 30, 2025 |
| NCT04034173 | Not yet recruiting | Phase 2 | Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation | August 1, 2019 | August 1, 2026 |
| NCT05314998 | Not yet recruiting | Phase 3 | Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature | June 15, 2024 | September 1, 2031 |
| NCT06394713 | Not yet recruiting | Phase 1/Phase 2 | A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors | June 15, 2024 | December 15, 2026 |
| NCT05322499 | Not yet recruiting | Phase 2 | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | April 15, 2022 | April 15, 2025 |
| NCT05732129 | Not yet recruiting | Phase 2 | The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer. | March 1, 2023 | December 31, 2023 |
| NCT06238843 | Not yet recruiting | Phase 3 | A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma | March 29, 2024 | June 30, 2027 |
| NCT06459180 | Not yet recruiting | Phase 3 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | July 5, 2024 | October 23, 2028 |
| NCT05643677 | Not yet recruiting | Phase 2 | Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer | December 2022 | November 2025 |
| NCT03554707 | Not yet recruiting | Early Phase 1 | SGT-53 in Children With Recurrent or Progressive CNS Malignancies | June 2022 | December 2024 |
| NCT04443543 | Not yet recruiting | Phase 2 | An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer | June 22, 2020 | December 31, 2026 |
| NCT06166589 | Not yet recruiting | Phase 2 | Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer | January 1, 2024 | January 1, 2027 |
| NCT05669807 | Not yet recruiting | Phase 2 | Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer | December 2022 | November 2025 |
| NCT06139211 | Not yet recruiting | Phase 1/Phase 2 | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | November 30, 2023 | April 30, 2026 |
| NCT06450041 | Not yet recruiting | Phase 2 | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | July 2024 | December 2038 |
| NCT06381154 | Not yet recruiting | Phase 2 | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer | June 30, 2024 | July 4, 2029 |
| NCT06089330 | Not yet recruiting | Phase 2 | A Study of JMT101 in Patients With Metastatic Colorectal Cancer | January 2024 | December 2024 |
| NCT04199026 | Not yet recruiting | Early Phase 1 | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | January 31, 2025 | December 31, 2025 |
| NCT05846867 | Not yet recruiting | Phase 1/Phase 2 | Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients | May 10, 2023 | July 10, 2025 |
| NCT06351020 | Not yet recruiting | Phase 3 | LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. | April 1, 2024 | December 15, 2026 |
| NCT06401330 | Not yet recruiting | Phase 3 | A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | June 12, 2024 | February 13, 2031 |
| NCT05031975 | Recruiting | Phase 2 | Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy | May 2, 2022 | June 1, 2024 |
| NCT05462236 | Recruiting | Phase 2 | MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer | April 14, 2023 | October 15, 2026 |
| NCT05546853 | Recruiting | Phase 1 | Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma | March 28, 2023 | November 28, 2025 |
| NCT05610163 | Recruiting | Phase 2 | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation | December 8, 2022 | September 2032 |
| NCT05620862 | Recruiting | Phase 1 | Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors | October 25, 2022 | June 1, 2025 |
| NCT05628038 | Recruiting | Phase 2 | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer | August 18, 2022 | December 1, 2025 |
| NCT05677490 | Recruiting | Phase 3 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | January 23, 2023 | November 8, 2028 |
| NCT02611024 | Recruiting | Phase 1/Phase 2 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | May 6, 2016 | March 2026 |
| NCT05694715 | Recruiting | Phase 1 | Combination Therapy in Cancers With Mutations in DNA Repair Genes | May 23, 2023 | January 31, 2028 |
| NCT05722327 | Recruiting | Phase 1 | Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | December 6, 2023 | September 30, 2027 |
| NCT05727163 | Recruiting | Phase 2 | FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients | July 29, 2022 | December 31, 2026 |
| NCT05731518 | Recruiting | Phase 1/Phase 2 | SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | February 23, 2023 | February 28, 2026 |
| NCT05737563 | Recruiting | Phase 3 | PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC | February 17, 2023 | February 17, 2026 |
| NCT05800587 | Recruiting | Phase 2 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | February 22, 2023 | August 1, 2029 |
| NCT05818982 | Recruiting | Phase 2 | To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC | February 9, 2023 | February 2026 |
| NCT02813135 | Recruiting | Phase 1/Phase 2 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | August 3, 2016 | August 2027 |
| NCT02885753 | Recruiting | Phase 3 | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver | December 2016 | September 2027 |
| NCT05838768 | Recruiting | Phase 1 | Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | June 27, 2023 | January 31, 2030 |
| NCT05839470 | Recruiting | Phase 2 | Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer | November 19, 2023 | March 1, 2025 |
| NCT05843188 | Recruiting | Phase 2 | Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | August 9, 2023 | October 24, 2026 |
| NCT05863195 | Recruiting | Phase 3 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | October 19, 2023 | June 30, 2034 |
| NCT05945823 | Recruiting | Phase 2 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | July 13, 2023 | May 2025 |
| NCT05999994 | Recruiting | Phase 2 | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | January 22, 2020 | May 1, 2026 |
| NCT06003998 | Recruiting | Phase 2 | Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab | December 27, 2022 | January 1, 2025 |
| NCT06006273 | Recruiting | Phase 1/Phase 2 | A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors | August 16, 2023 | December 31, 2028 |
| NCT06011772 | Recruiting | Early Phase 1 | EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | December 4, 2023 | December 4, 2026 |
| NCT06013618 | Recruiting | Phase 2 | Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma | June 19, 2023 | December 31, 2024 |
| NCT06094140 | Recruiting | Phase 2 | NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer | May 20, 2022 | June 2026 |
| NCT06107413 | Recruiting | Phase 2 | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | November 12, 2023 | October 1, 2026 |
| NCT03366155 | Recruiting | Phase 2 | Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | June 24, 2019 | December 30, 2030 |
| NCT03403101 | Recruiting | Phase 2 | The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer | July 1, 2020 | July 1, 2024 |
| NCT06169202 | Recruiting | A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients | June 1, 2023 | June 2025 | |
| NCT06172296 | Recruiting | Phase 3 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | April 19, 2024 | December 31, 2029 |
| NCT06194734 | Recruiting | Phase 3 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | February 5, 2024 | December 30, 2027 |
| NCT03715933 | Recruiting | Phase 1 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | October 10, 2018 | July 2026 |
| NCT06219941 | Recruiting | Phase 2 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | December 13, 2023 | January 19, 2027 |
| NCT03829462 | Recruiting | Phase 3 | Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients | March 28, 2019 | September 2025 |
| NCT03872947 | Recruiting | Phase 1 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | April 26, 2019 | March 2025 |
| NCT06304974 | Recruiting | Phase 3 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | March 19, 2024 | May 2026 |
| NCT04008030 | Recruiting | Phase 3 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | August 5, 2019 | June 10, 2026 |
| NCT06346392 | Recruiting | Phase 3 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | March 4, 2024 | October 9, 2026 |
| NCT04141995 | Recruiting | Phase 2 | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | February 12, 2021 | February 2025 |
| NCT04189055 | Recruiting | Phase 2 | Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. | January 7, 2020 | July 2024 |
| NCT04205968 | Recruiting | Phase 2 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | June 1, 2020 | June 16, 2025 |
| NCT04211675 | Recruiting | Phase 1/Phase 2 | NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab | September 1, 2022 | December 2025 |
| NCT04221035 | Recruiting | Phase 3 | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | November 5, 2019 | November 2032 |
| NCT04239092 | Recruiting | Phase 1 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | June 5, 2020 | December 2024 |
| NCT06356311 | Recruiting | Phase 3 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | May 3, 2024 | May 5, 2028 |
| NCT04322318 | Recruiting | Phase 2 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | October 19, 2020 | July 1, 2027 |
| NCT04329494 | Recruiting | Phase 1 | PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | August 21, 2020 | December 30, 2025 |
| NCT04358354 | Recruiting | Phase 3 | Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer | October 22, 2020 | December 31, 2024 |
| NCT04361708 | Recruiting | Phase 1 | Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | May 8, 2020 | May 2027 |
| NCT04393584 | Recruiting | Phase 2/Phase 3 | FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma | January 29, 2019 | January 1, 2026 |
| NCT04442984 | Recruiting | Phase 2 | FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III) | November 3, 2019 | November 3, 2024 |
| NCT04587128 | Recruiting | Phase 2 | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | October 19, 2020 | October 2025 |
| NCT04607421 | Recruiting | Phase 3 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | December 21, 2020 | November 15, 2026 |
| NCT04625907 | Recruiting | Phase 1/Phase 2 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma | September 17, 2020 | June 2030 |
| NCT04657068 | Recruiting | Phase 1/Phase 2 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | December 13, 2020 | June 2025 |
| NCT04753879 | Recruiting | Phase 2 | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | September 29, 2021 | December 1, 2029 |
| NCT04796012 | Recruiting | Phase 1/Phase 2 | VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | April 18, 2023 | January 2025 |
| NCT06417476 | Recruiting | Phase 2 | Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer | December 12, 2022 | December 2025 |
| NCT04861558 | Recruiting | Phase 3 | Efficacy of Hyperthermic Intraperitoneal Chemotherapy | May 1, 2021 | December 2029 |
| NCT04920032 | Recruiting | Phase 1 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | August 26, 2021 | December 31, 2025 |
| NCT05022654 | Recruiting | Phase 2 | SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. | December 13, 2021 | April 2024 |
| NCT05049863 | Recruiting | Phase 1/Phase 2 | Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) | February 27, 2023 | October 31, 2025 |
| NCT05062317 | Recruiting | Phase 2 | ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases | April 26, 2022 | February 28, 2026 |
| NCT05062889 | Recruiting | Phase 2 | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients | May 17, 2023 | December 2027 |
| NCT05153239 | Recruiting | Phase 3 | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | July 22, 2022 | April 2026 |
| NCT01837862 | Recruiting | Phase 1/Phase 2 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | October 22, 2013 | April 2025 |
| NCT05160727 | Recruiting | Phase 2 | Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer | October 1, 2021 | October 2024 |
| NCT05160896 | Recruiting | Phase 2 | SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer | November 12, 2021 | June 30, 2023 |
| NCT05229003 | Recruiting | Phase 2 | Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | March 9, 2022 | September 30, 2024 |
| NCT05235542 | Recruiting | Phase 1/Phase 2 | A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors | July 12, 2022 | March 2024 |
| NCT05239741 | Recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | April 2, 2022 | November 10, 2026 |
| NCT05286814 | Recruiting | Phase 2 | M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma | October 24, 2022 | December 31, 2028 |
| NCT05319639 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | February 16, 2023 | December 31, 2024 |
| NCT05319730 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | May 16, 2023 | September 20, 2028 |
| NCT02087475 | Recruiting | Phase 3 | Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin | January 2011 | December 2024 |
| NCT05379595 | Recruiting | Phase 1/Phase 2 | A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | July 29, 2022 | April 27, 2027 |
| NCT05379790 | Recruiting | Phase 1 | Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin | May 25, 2022 | August 2024 |
| NCT05382442 | Recruiting | Phase 2 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | July 27, 2022 | December 25, 2026 |
| NCT05384821 | Recruiting | Phase 1/Phase 2 | Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) | September 14, 2022 | October 2028 |
| NCT05391126 | Recruiting | N/A | GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care | September 28, 2022 | May 2025 |
| NCT05417386 | Recruiting | Phase 1 | FOLFIRINOX + NIS793 in Pancreatic Cancer | August 9, 2022 | May 1, 2025 |
| NCT05440786 | Recruiting | Phase 2 | CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma | September 20, 2022 | September 10, 2028 |
| NCT05669339 | Suspended | Phase 1 | AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | June 2024 | April 2026 |
| NCT00209664 | Suspended | Phase 2 | Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer | January 2004 | December 2008 |
| NCT05688215 | Suspended | Phase 1/Phase 2 | Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | March 7, 2023 | May 1, 2026 |
| NCT00033306 | Terminated | Phase 2 | BMS-247550 in Treating Patients With Metastatic Colorectal Cancer | February 2002 | July 2005 |
| NCT00106262 | Terminated | Phase 2 | Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer | March 2005 | March 2007 |
| NCT02485834 | Terminated | Phase 2 | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer | August 2015 | August 2018 |
| NCT02423954 | Terminated | Phase 1/Phase 2 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | April 2015 | November 1, 2017 |
| NCT00671801 | Terminated | Phase 1 | Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I | April 29, 2008 | February 2014 |
| NCT01479465 | Terminated | Phase 2 | Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma | December 2011 | February 2015 |
| NCT03879798 | Terminated | Phase 1/Phase 2 | DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer | March 15, 2019 | May 2, 2023 |
| NCT01505608 | Terminated | Phase 1/Phase 2 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | December 2011 | December 2014 |
| NCT00960063 | Terminated | Phase 1 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | November 11, 2009 | December 22, 2010 |
| NCT01858662 | Terminated | Phase 2 | Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors | January 2014 | November 2015 |
| NCT01550510 | Terminated | Phase 1/Phase 2 | Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA | December 2011 | February 2015 |
| NCT05546411 | Terminated | Phase 2 | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | January 6, 2023 | October 13, 2023 |
| NCT01014767 | Terminated | Phase 3 | Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors | November 2009 | January 2014 |
| NCT00053833 | Terminated | Phase 2 | S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | April 2003 | July 2004 |
| NCT00969033 | Terminated | Phase 2 | CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin | July 2009 | December 2011 |
| NCT02283359 | Terminated | Phase 1 | Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus | December 2014 | January 2016 |
| NCT01607554 | Terminated | Phase 1/Phase 2 | Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer | April 2012 | March 2013 |
| NCT01609231 | Terminated | Phase 2 | A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) | July 6, 2012 | December 9, 2014 |
| NCT00755534 | Terminated | Phase 2 | Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC | November 2008 | November 2008 |
| NCT01016860 | Terminated | Phase 1 | OSI-906 and Irinotecan in Patients With Advanced Cancer | December 2009 | April 2013 |
| NCT03722108 | Terminated | Phase 1/Phase 2 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas | February 7, 2019 | May 19, 2022 |
| NCT00077233 | Terminated | Phase 3 | FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum | December 2003 | June 2010 |
| NCT00040391 | Terminated | Phase 2 | A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer | June 2002 | |
| NCT00473616 | Terminated | Phase 1 | Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan | May 2007 | January 2011 |
| NCT03500874 | Terminated | Phase 3 | Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM | May 28, 2018 | August 31, 2021 |
| NCT05039944 | Terminated | Phase 2 | SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies | November 30, 2021 | June 6, 2022 |
| NCT01060423 | Terminated | Phase 2 | TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer | February 2010 | May 2015 |
| NCT00848783 | Terminated | Phase 2 | Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers | May 2008 | September 2012 |
| NCT03009058 | Terminated | Phase 1/Phase 2 | Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer | May 24, 2017 | August 30, 2017 |
| NCT00845039 | Terminated | Phase 2 | A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab | May 2009 | February 2011 |
| NCT00642603 | Terminated | Phase 2 | A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer | May 2008 | March 2009 |
| NCT00449163 | Terminated | Phase 2 | Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer | March 1, 2006 | March 2010 |
| NCT00642746 | Terminated | Phase 2 | Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) | March 2008 | December 2011 |
| NCT03495921 | Terminated | Phase 3 | A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide | August 21, 2018 | January 20, 2022 |
| NCT00177853 | Terminated | Phase 1 | Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer | December 2006 | July 2010 |
| NCT02331251 | Terminated | Phase 1/Phase 2 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | December 2014 | January 2018 |
| NCT00314353 | Terminated | Phase 2 | Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon | March 2006 | June 2010 |
| NCT01017653 | Terminated | Phase 2 | Panitumumab and Irinotecan for Malignant Gliomas | February 2010 | October 2011 |
| NCT02316496 | Terminated | Phase 2 | Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study | September 23, 2015 | January 2017 |
| NCT00276744 | Terminated | Phase 2 | Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | October 2005 | April 2010 |
| NCT01765582 | Terminated | Phase 2 | Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer | January 23, 2013 | March 14, 2016 |
| NCT00264134 | Terminated | Phase 1/Phase 2 | Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer | June 2003 | October 2005 |
| NCT00256269 | Terminated | Phase 2 | Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma | June 2005 | February 7, 2007 |
| NCT01925274 | Terminated | Phase 2 | A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer | November 15, 2013 | April 6, 2016 |
| NCT00838578 | Terminated | Phase 1/Phase 2 | Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer | March 2009 | October 2012 |
| NCT00816777 | Terminated | Phase 1/Phase 2 | Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer | December 2008 | March 2011 |
| NCT02801097 | Terminated | Phase 1 | RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) | August 30, 2016 | December 9, 2019 |
| NCT01813253 | Terminated | Phase 3 | Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer | May 13, 2013 | February 19, 2018 |
| NCT03251417 | Terminated | Phase 2 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma | September 10, 2017 | April 25, 2021 |
| NCT00811993 | Terminated | Phase 1 | A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors | February 2009 | December 2012 |
| NCT00954512 | Terminated | Phase 1/Phase 2 | Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | September 25, 2009 | June 7, 2011 |
| NCT05148195 | Terminated | Phase 2 | A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors | December 22, 2021 | July 26, 2023 |
| NCT05461794 | Terminated | Phase 2 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma | October 3, 2022 | February 26, 2024 |
| NCT00717990 | Terminated | Phase 2 | Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment | April 2008 | December 2012 |
| NCT00808899 | Terminated | Phase 2 | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma | December 2008 | July 2009 |
| NCT00361244 | Terminated | Phase 1/Phase 2 | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | July 2006 | August 2010 |
| NCT00037180 | Terminated | Phase 2 | For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy | April 2002 | January 2003 |
| NCT03368859 | Terminated | Phase 2 | A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab | March 20, 2018 | December 18, 2019 |
| NCT02842580 | Terminated | Phase 2 | De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer | September 2016 | October 2020 |
| NCT02275806 | Terminated | Phase 2 | Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC | October 2014 | September 27, 2017 |
| NCT00681876 | Terminated | Phase 2 | Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer | April 2008 | February 2010 |
| NCT01313884 | Terminated | Phase 2 | Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma | May 2011 | July 2014 |
| NCT01336985 | Terminated | Phase 1 | Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads | March 28, 2011 | March 28, 2011 |
| NCT01347866 | Terminated | Phase 1 | Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer | October 2011 | December 2015 |
| NCT01367275 | Terminated | Phase 2 | Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | August 2011 | November 2013 |
| NCT00320320 | Terminated | Phase 2 | Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer | April 2005 | April 2007 |
| NCT03678428 | Terminated | Phase 3 | FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM | December 31, 2021 | December 31, 2022 |
| NCT00216086 | Terminated | Phase 2 | Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer | May 2005 | May 2008 |
| NCT00755118 | Terminated | Phase 2 | Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc | October 2008 | August 2012 |
| NCT04833036 | Unknown status | Phase 2 | c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI | October 1, 2019 | November 2022 |
| NCT01859728 | Unknown status | Phase 2 | GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer | January 2013 | December 2018 |
| NCT03751176 | Unknown status | Phase 2 | Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal | November 8, 2018 | November 30, 2022 |
| NCT02662959 | Unknown status | Phase 2 | Irinotecan as 3rd Line Therapy in Gastric Cancer | April 2015 | |
| NCT03792269 | Unknown status | Phase 2 | Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC | January 1, 2016 | December 2020 |
| NCT03797625 | Unknown status | Phase 2 | Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas | May 4, 2017 | December 31, 2021 |
| NCT03823079 | Unknown status | Phase 2 | Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia | February 1, 2019 | February 1, 2020 |
| NCT03963193 | Unknown status | Phase 2 | Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type | June 1, 2019 | June 1, 2021 |
| NCT02453464 | Unknown status | Phase 1 | A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer | August 2015 | |
| NCT02624726 | Unknown status | Phase 2 | Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment | January 2016 | March 2019 |
| NCT00509964 | Unknown status | Phase 2 | Second-Line Irinotecan vs. ILF for AGC | May 2007 | July 2007 |
| NCT04072198 | Unknown status | Phase 2 | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients | September 26, 2019 | September 2022 |
| NCT02605265 | Unknown status | Phase 3 | Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 | October 2015 | December 2020 |
| NCT00507143 | Unknown status | N/A | Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan | August 2006 | December 2008 |
| NCT04101929 | Unknown status | Phase 2 | Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen | October 1, 2019 | December 31, 2021 |
| NCT00433927 | Unknown status | Phase 3 | 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) | January 2007 | December 2016 |
| NCT02339116 | Unknown status | Phase 3 | Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC | February 26, 2015 | February 2021 |
| NCT01930864 | Unknown status | Phase 2 | Metformin Plus Irinotecan for Refractory Colorectal Cancer | September 1, 2015 | December 1, 2020 |
| NCT04337879 | Unknown status | Phase 1/Phase 2 | A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer | July 20, 2020 | December 31, 2020 |
| NCT04342910 | Unknown status | Phase 3 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | September 21, 2020 | September 1, 2022 |
| NCT04358341 | Unknown status | Phase 2 | Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer | June 17, 2020 | December 1, 2022 |
| NCT01977235 | Unknown status | Phase 2 | Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer | September 2013 | September 2017 |
| NCT00320294 | Unknown status | Phase 2 | ILF With/Without Cisplatin for Advanced Gastric Cancer | February 2005 | March 2007 |
| NCT04394598 | Unknown status | Phase 2 | A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer | March 1, 2020 | December 1, 2022 |
| NCT04411524 | Unknown status | Phase 2 | The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer | July 1, 2020 | December 31, 2022 |
| NCT04411537 | Unknown status | Phase 2 | The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer | July 1, 2020 | December 31, 2022 |
| NCT02021422 | Unknown status | Phase 1 | A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy | June 2013 | December 2017 |
| NCT00319800 | Unknown status | Phase 2 | Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC | February 2006 | March 2007 |
| NCT04453930 | Unknown status | Phase 2 | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | June 8, 2020 | June 2023 |
| NCT01224652 | Unknown status | Phase 3 | Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy | ||
| NCT02395068 | Unknown status | Phase 1 | Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors | November 2012 | December 2015 |
| NCT01239485 | Unknown status | Phase 1 | Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents | November 2010 | December 2013 |
| NCT01249638 | Unknown status | Phase 3 | Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC | December 2010 | December 2016 |
| NCT02030678 | Unknown status | Phase 2 | A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer | September 2014 | December 2020 |
| NCT02296203 | Unknown status | Phase 2 | Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). | October 2014 | June 15, 2018 |
| NCT04689347 | Unknown status | Phase 1 | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | January 1, 2021 | January 2023 |
| NCT01380275 | Unknown status | Phase 2 | Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas. | April 2008 | December 2014 |
| NCT02515734 | Unknown status | Phase 2 | A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab | August 2015 | June 2020 |
| NCT04776655 | Unknown status | Phase 3 | Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB | April 30, 2021 | April 29, 2024 |
| NCT02071069 | Unknown status | Phase 2 | Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer | July 2013 | July 2016 |
| NCT01474187 | Unknown status | Phase 1 | Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer | November 2011 | December 2012 |
| NCT01494363 | Unknown status | Phase 2 | Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer | October 2011 | December 2013 |
| NCT01566942 | Unknown status | Phase 3 | FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer | June 2012 | June 2017 |
| NCT04985201 | Unknown status | Phase 2 | Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy | November 1, 2021 | August 1, 2023 |
| NCT04988191 | Unknown status | Phase 1/Phase 2 | Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer | December 24, 2020 | December 24, 2023 |
| NCT01635400 | Unknown status | Phase 2 | Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer | June 2012 | June 2014 |
| NCT05018182 | Unknown status | Phase 2 | FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer | August 2, 2021 | August 2, 2022 |
| NCT02376452 | Unknown status | Phase 2 | Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients | September 2014 | December 2016 |
| NCT02935764 | Unknown status | Phase 3 | FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients | October 2016 | |
| NCT03030937 | Unknown status | Phase 2 | Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA | February 1, 2017 | December 30, 2018 |
| NCT03045770 | Unknown status | N/A | mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA | February 10, 2017 | December 30, 2019 |
| NCT03053167 | Unknown status | Phase 2 | Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients | December 2016 | December 2020 |
| NCT03061058 | Unknown status | Phase 3 | Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC | April 1, 2013 | December 2019 |
| NCT00874328 | Unknown status | Phase 1/Phase 2 | A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | October 2008 | December 2012 |
| NCT03116555 | Unknown status | Phase 2 | Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA | April 5, 2017 | September 2020 |
| NCT03126071 | Unknown status | Phase 2 | Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer | February 15, 2017 | February 15, 2023 |
| NCT01729481 | Unknown status | Phase 2 | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer | July 2012 | December 2017 |
| NCT01802645 | Unknown status | Phase 2 | Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases | March 2013 | December 2020 |
| NCT03167112 | Unknown status | Phase 2 | A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer | July 3, 2017 | May 2018 |
| NCT03175016 | Unknown status | Phase 2/Phase 3 | Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer | June 20, 2017 | December 2019 |
| NCT02319187 | Unknown status | Phase 3 | Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial | December 2014 | June 2017 |
| NCT03316326 | Unknown status | Phase 2 | S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer | November 1, 2017 | December 31, 2021 |
| NCT02171325 | Unknown status | Phase 2 | Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment | June 2014 | June 2021 |
| NCT03329183 | Unknown status | Phase 2 | High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28 | March 2019 | March 2022 |
| NCT01826396 | Unknown status | Phase 2 | Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer | April 2013 | December 2014 |
| NCT03400592 | Unknown status | Phase 2 | Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma | June 2015 | June 2018 |
| NCT02348450 | Unknown status | Phase 4 | Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer | February 2015 | December 2018 |
| NCT03416517 | Unknown status | Phase 1/Phase 2 | Anlotinib and Irinotecan for Ewing Sarcoma | January 22, 2018 | December 2020 |
| NCT03443492 | Unknown status | Phase 2 | SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer | March 26, 2018 | December 31, 2020 |
| NCT03503604 | Unknown status | Phase 1 | A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | May 1, 2018 | March 1, 2019 |
| NCT03522649 | Unknown status | Phase 3 | A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer | April 12, 2018 | November 2021 |
| NCT03562390 | Unknown status | Phase 2 | Irinotecan for Advanced and Metastatic Breast Cancer | April 1, 2017 | December 2021 |
| NCT03567629 | Unknown status | Phase 2 | Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer | May 29, 2018 | December 30, 2023 |
| NCT03607643 | Unknown status | Phase 1/Phase 2 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | January 15, 2019 | December 15, 2020 |
| NCT03608046 | Unknown status | Phase 2 | Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer | October 3, 2018 | December 31, 2023 |
| NCT03613753 | Unknown status | Phase 2 | Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer | June 1, 2018 | June 1, 2021 |
| NCT03651219 | Unknown status | Phase 3 | Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer | September 8, 2018 | August 8, 2020 |
| NCT03668418 | Unknown status | Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos | June 1, 2018 | May 31, 2022 | |
| NCT03702985 | Unknown status | Phase 2 | Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer | May 28, 2018 | March 1, 2020 |
| NCT03711240 | Unknown status | Phase 2 | The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases | January 8, 2019 | October 30, 2020 |
| NCT03387904 | Unknown status | Phase 2 | Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma | January 13, 2019 | December 1, 2022 |
| NCT03380689 | Withdrawn | Phase 1 | Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer | January 5, 2018 | January 5, 2019 |
| NCT04943627 | Withdrawn | Phase 3 | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | August 2, 2021 | October 22, 2021 |
| NCT02747537 | Withdrawn | Phase 2 | Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan | June 24, 2016 | February 29, 2020 |
| NCT02046538 | Withdrawn | Phase 2 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | February 2014 | February 2018 |
| NCT00577109 | Withdrawn | Phase 2 | A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer. | December 2007 | June 2012 |
| NCT03222089 | Withdrawn | Phase 2 | Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | July 20, 2017 | July 20, 2020 |
| NCT05177276 | Withdrawn | Phase 1/Phase 2 | Selinexor Combination Ph 1 Study | September 2014 | September 2015 |
| NCT01847495 | Withdrawn | N/A | Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis | October 2013 | November 29, 2017 |
| NCT00766220 | Withdrawn | Phase 2 | Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver | October 2009 | January 2012 |
| NCT00984438 | Withdrawn | Phase 1/Phase 2 | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme | June 2009 | June 2010 |
| NCT05042934 | Withdrawn | Phase 1/Phase 2 | Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma | September 15, 2021 | August 30, 2022 |
| NCT01654081 | Withdrawn | Phase 2 | A Protocol of Irinotecan for Carcinoma of the Lung | October 2013 | May 2014 |
| NCT00233623 | Withdrawn | Phase 2 | Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer | July 2004 | January 2006 |
| NCT05238831 | Withdrawn | Early Phase 1 | SMMART Adaptive Clinical Treatment (ACT) Trial | January 30, 2023 | May 31, 2026 |
| NCT01631539 | Withdrawn | N/A | Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC | September 2012 | December 2014 |